ESMO Congress 2023
ESMO Congress 2023
Advertisement
Mary GreccoESMO Congress 2023 | January 30, 2024
A study aimed to evaluate the feasibility of ddPCR to detect specific driver gene mutations in patients with resected NSCLC.
Read More
Katy MarshallPancreatic Cancer | November 3, 2023
Participating patients received PERT at baseline or within 3 months of receiving first-line treatment.
Katy MarshallGEP-NETs | November 3, 2023
Researchers analyzed cabozantinib's ability to improve the progression-free survival rate for patients.
Rob DillardESMO Congress 2023 | October 26, 2023
Perioperative immunotherapy both before and after surgery significantly improves EFS in operable early-stage NSCLC.
Rob DillardESMO Congress 2023 | October 23, 2023
Immune evasion alterations impact the duration of response to checkpoint inhibitors in patients with metastatic NSCLC.
Rob DillardESMO Congress 2023 | October 20, 2023
Neoadjuvant pembrolizumab in combination with chemotherapy followed by resection and adjuvant pembro improves OS in NSCLC.
Rob DillardESMO Congress 2023 | October 20, 2023
Dostarlimab and chemotherapy combo demonstrates robust safety and efficacy in treating metastatic nonsquamous NSCLC.
Advertisement
Advertisement
Advertisement
Latest News

February 27, 2024